Prime Medicine, Inc. secured a favorable arbitration ruling against Beam Therapeutics, allowing continued development of its PM647 gene editing program for AATD. PRME's Prime Editing platform offers precise, versatile gene correction using LNP delivery, but remains preclinical with IND/CTA filings for PM647 expected mid-2026 and initial clinical data in 2027. PRME lags competitors like Beam, Sanofi, and Arrowhead in the AATD development race, facing significant funding needs and clinical risks.

seekingalpha.com - 2026-07-09 10:22:58

Prime Medicine Inc. (NASDAQ:PRME) said it secured a favorable, binding arbitration ruling in its dispute with Beam Therapeutics Inc. (NASDAQ:BEAM).

benzinga.com - 2026-07-08 13:29:41

Gene-editing is a handy tool for developing sophisticated medicines. A new CRISPR molecule can destroy cells that express specific signals.

fool.com - 2026-07-08 05:45:00

Fresh short‑interest data for late June shows a tightly packed group of mid‑ and large‑cap names where bearish positioning has reached extreme territory, setting the stage for violent moves if sentiment flips.

benzinga.com - 2026-06-29 10:35:25

Beam Therapeutics gains after the FDA clears the IND for BEAM-304 in PKU, advancing its liver-targeted gene-editing program into clinical testing.

zacks.com - 2026-06-19 11:36:04

BEAM-304 Development Approach Has Potential to Create Transformative, One-time Therapies for the Majority of Patients with PKU  BEAM-304 Program Designed as Platform-based Approach Reflecting Emerging FDA Guidance for Accelerated Development of Genome Editing Therapies New Preclinical Data for BEAM-304 to be Presented at FASEB Genome Engineering: Research and Applications Conference CAMBRIDGE, Mass., June 18, 2026 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that the United States (U.S.) Food and Drug Administration (FDA) has cleared the investigational new drug (IND) application for BEAM-304 for the treatment of phenylketonuria (PKU).

globenewswire.com - 2026-06-18 07:00:00

In this week's edition of InnovationRx, we look at biotech M&A, the rise of India's Anthem Biosciences, and more. To get it in your inbox, subscribe here.

forbes.com - 2026-06-17 12:30:08

BEAM shares jump 21% in three months as promising BEAM-302 data, pipeline milestones and a cash runway into mid-2029 boost investor confidence.

zacks.com - 2026-06-16 09:51:26

Genomics and synthetic biology are reshaping healthcare, with growing demand for precision medicine spotlighting stocks like PACB, MYGN and TWST.

zacks.com - 2026-06-02 13:10:18

Beam Therapeutics Inc. (BEAM) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript

seekingalpha.com - 2026-05-25 13:37:05

Beam Therapeutics NASDAQ: BEAM Chief Executive Officer John Evans said the company is advancing its base-editing platform across hematology and liver disease programs, with a potential biologics license application for its sickle cell disease candidate possible as early as the end of this year.

marketbeat.com - 2026-05-20 14:05:29

Presentation Features Additional Data from the Single-dose Cohorts of the Phase 1/2 Trial, Including Detailed Safety Results, Efficacy Durability and Reduction in Human Neutrophil Elastase Activity Post-BEAM-302 Treatment Presentation Features Additional Data from the Single-dose Cohorts of the Phase 1/2 Trial, Including Detailed Safety Results, Efficacy Durability and Reduction in Human Neutrophil Elastase Activity Post-BEAM-302 Treatment

globenewswire.com - 2026-05-18 16:00:00

Beam Therapeutics develops precision genetic medicines using base editing technology to target serious inherited diseases.

fool.com - 2026-05-18 14:05:44

Beam Therapeutics Supports AlphaDetect to Accelerate Detection of Alpha-1 PR Newswire DURHAM, N.C., May 13, 2026

gurufocus.com - 2026-05-13 12:00:00

The sponsorship helps expand proven strategies to consistently detect a genetic, irreversible, and progressive condition in patients with liver and/or lung disease. DURHAM, N.C.

prnewswire.com - 2026-05-13 11:49:00

Beam Therapeutics is transitioning from a scientific platform to a late-stage genetic medicine company with a clear commercial bridge. BEAM's $1.2B cash position supports a runway into mid-2029, enabling pivotal programs in sickle cell disease (Risto-cel) and AATD (BEAM-302). Risto-cel targets process efficiency and efficacy in SCD, with a potential BLA submission by year-end 2026; BEAM-302 pursues accelerated approval in AATD.

seekingalpha.com - 2026-05-13 09:46:02

CAMBRIDGE, Mass., May 13, 2026 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that John Evans, chief executive officer of Beam, will present at the 2026 RBC Capital Markets Healthcare Conference on Wednesday, May 20, 2026, at 10:30 a.m. ET in New York.

globenewswire.com - 2026-05-13 07:00:00

CAMBRIDGE, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that the company will present updated biomarker data from the BEACON Phase 1/2 clinical trial of ristoglogene autogetemcel (risto-cel) in sickle cell disease (SCD) at the European Hematology Association 2026 Congress (EHA2026), taking place June 11-14, 2026, in Stockholm, Sweden. Risto-cel is an investigational autologous cell therapy with a potential best-in-class profile for the treatment of SCD.

globenewswire.com - 2026-05-12 09:30:00

Beam Therapeutics Q1 revenues beat estimates as its gene-editing pipeline advanced, with key updates across the SCD, AATD and PKU programs.

zacks.com - 2026-05-08 13:11:19

Beam Therapeutics Inc. (BEAM) came out with a quarterly loss of $0.91 per share versus the Zacks Consensus Estimate of a loss of $0.87. This compares to a loss of $1.24 per share a year ago.

zacks.com - 2026-05-07 09:56:27

Recent BEAM-302 Topline Data in Alpha-1 Antitrypsin Deficiency (AATD) Demonstrate Strong Single-dose Safety and Efficacy Profile, with 60 mg Selected as Optimal Biological Dose; Global Pivotal Cohort Expected to Initiate in Second Half of 2026 Data from Phase 1/2 BEACON Clinical Trial of Risto-cel in Sickle Cell Disease Published in April 1 Issue of the New England Journal of Medicine; U.S. Biologics License Application (BLA) Submission Expected as Early as Year-End 2026 Investigational New Drug (IND) Application for BEAM-304 in PKU and Data from BEAM-301 in GSDIa Anticipated in 2026 Ended First Quarter 2026 with $1.2 Billion in Cash, Cash Equivalents and Marketable Securities; Cash Runway Expected to Support Operating Plans into mid-2029 CAMBRIDGE, Mass., May 07, 2026 (GLOBE NEWSWIRE) --   Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today reported first quarter 2026 financial results and provided updates across the company's hematology and genetic disease franchises.

globenewswire.com - 2026-05-07 07:00:00

Concurrent Investment Advisors LLC acquired a new stake in Beam Therapeutics Inc. (NASDAQ: BEAM) in the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 76,825 shares of the company's stock, valued at approximately $2,130,000. Concurrent Investment Advisors LLC owned approximately 0.08% of Beam Therapeutics

defenseworld.net - 2026-04-29 14:10:58

On CNBC's “Mad Money Lightning Round,” Jim Cramer said Ondas Inc (NASDAQ:ONDS) is losing a lot of money and added that he would rather have to find something new and different that is distinct, while he doesn't see anything distinct about Ondas.

benzinga.com - 2026-04-29 08:27:32

Biotechnology stocks have seen a spike in merger and acquisition (M&A) activity. In March 2026 alone, there were 10 deals valued at approximately $31.5 billion.

marketbeat.com - 2026-04-27 07:06:01